The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of paclitaxel and capecitabine (PX) combination as neoadjuvant chemotherapy for unresectable locally advanced gastric cancer.
Yoon Ho Ko
No relevant relationships to disclose
Sook Hee Hong
No relevant relationships to disclose
Sang Young Roh
No relevant relationships to disclose
Kyo Young Song
No relevant relationships to disclose
Eun Sun Jung
No relevant relationships to disclose
Hae Myung Jeon
No relevant relationships to disclose
Cho Hyun Park
No relevant relationships to disclose
Young Seon Hong
No relevant relationships to disclose